107 results
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
.
The newly composed Board immediately moved into action by affirming its commitment to employing governance best practices for a company of our size and stage … is now undertaking a comprehensive review of each committee’s charter, seeking to push forward in our commitment to governance best practices in every
8-K/A
EX-99.3
syl8dr1
5 Feb 24
Financial Statements and Exhibits
12:00am
8-K
EX-99.1
91rm262 fv
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
424B3
24ulqwfijbma3 iv
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
77sukrxy9u4huyymy5
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
6jd80z
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
DEFA14A
EX-99.1
8nd1k u7j3inm1s5m6ft
31 Aug 23
Additional proxy soliciting materials
5:25pm
8-K
EX-99.1
ulgxip6
31 Aug 23
Other Events
5:25pm
425
23ws6rs qr8xwj5o5ea4
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-10.1
xy7mmb5lnt0adlt7v
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.5
vixs6
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-99.1
b5tqk31z325en n4
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-2.1
hn6vfoyti sp2dlr
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am